 (1) (1).png){kind=logo}
- 02 Feb 2017, 21:00
#2020
Epidemiological data is also important in decision making, when there is need to rank what issues to tackle first and to understand the magnitude of the use. For each individual patient there are individual circumstances. An interesting use of pharmacoepidemiology data is the use of data for individual prescribers and giving feedback to their prescribing pattern compared with other prescribers as done in the Rx-Pad studies
(http://www.ncbi.nlm.nih.gov/pubmed/23894178)
Another example of use not on individual patients but in decision making was the recent issue of co-prescribing of different angiotensin-rening blockers (ARBs) and the increased risk of side-effects without added benefit. EMA then did a drug utilisation study to understand better how large the problem really was (not very large) and in what group of patients it was largest (most co-prescribing in the groups with the biggest risk as well) the report is publised on ENCEPP
here: http://www.encepp.eu/encepp/openAttachm ... esult/4612
(http://www.ncbi.nlm.nih.gov/pubmed/23894178)
Another example of use not on individual patients but in decision making was the recent issue of co-prescribing of different angiotensin-rening blockers (ARBs) and the increased risk of side-effects without added benefit. EMA then did a drug utilisation study to understand better how large the problem really was (not very large) and in what group of patients it was largest (most co-prescribing in the groups with the biggest risk as well) the report is publised on ENCEPP
here: http://www.encepp.eu/encepp/openAttachm ... esult/4612
